Table 1.
Individual data for the eight monkeys included in the present study.
| Mk-MO | Mk-VA | Mk-RO | Mk-BI | Mk-LL | Mk-MY | Mk-LY | Mk-MI | |
|---|---|---|---|---|---|---|---|---|
| BDA injection in | PMd/PMv | PMd/PMv | PMd | PMd/PMv | PMd/PMv | PMd/PMv | M1 | M1 |
| Age at sacrifice | 6 | 6 | 4.5 | 6 | 7.5 | 9.5 | 7.5 | 9.5 |
| Weight | 5.6 | 4.9 | 3.2 | 5 | 3.6 | 4.3 | 3.3 | 3.3 |
| Sex | Male | Male | Male | Male | Female | Female | Female | Female |
| Species | Fasc. | Fasc. | Fasc. | Fasc. | Fasc. | Fasc. | Fasc. | Fasc. |
| Type of lesion | MCI | MCI | MCI | MCI | MPTP | MPTP | MPTP | MPTP |
| Therapeutic treatment* | Nogo-A | Nogo-A | none | none | ANCE | ANCE | ANCE | ANCE |
| Nb. of series of sections | 5 | 5 | 5 | 5 | 10 | 10 | 10 | 10 |
| Intersections interval (μm) | 250 | 250 | 250 | 250 | 500 | 500 | 500 | 500 |
| Total BDA volume injected (μL) | 10.8 | 5 | 4.8 | 7.2 | 9.7 | 11.5 | 9 | 9 |
| Nb. of BDA injection sites | 12 | 5 | 6 | 11 | 8 | 9 | 6 | 6 |
| Body territory injected** | Large | Large | Large | Large | Large | Large | Large | Large |
| Volume lesion with ibotenic acid (mm3) | 41.8 | 20 | 14 | 20.1 | - | - | - | - |
| Loss DA neurons in SNpc (%) | - | - | - | - | 67.4 | 71.8 | 38.8 | 73.4 |
| Nb. labeled CS axons | 1,975 | 1,312 | 543 | 1,328 | 593 | 611 | 1,671 | 1,117 |
| Nb. boutons in SC | 207 | 1,372 | 3,802 | 2,799 | 543 | 3,323 | 318 | 170 |
| Nb. boutons in SCint | 23 | 138 | 2,242 | 1,409 | 126 | 1,255 | 12 | 112 |
| Nb. boutons in SCdeep | 129 | 1,081 | 992 | 902 | 322 | 1,736 | 212 | 52 |
| Corrected Nb. boutons in SC*** | 207 | 1,372 | 3,802 | 2,799 | 1,086 | 6,646 | 636 | 340 |
| Normalized Nb. boutons in SC**** | 105 | 1,046 | 7,002 | 2,108 | 1,831 | 10,877 | 381 | 304 |
SC, Superior Colliculus; SCint, intermediate nucleus of SC; SCdeep, deep nucleus of SC. Fasc., macaca fascicularis. Type of lesion: MCI: motor cortex injury, corresponding to a unilateral infusion of ibotenic acid in the hand area of the primary motor cortex (M1), as previously reported (Liu and Rouiller, 1999; Kaeser et al., 2010; Hoogewoud et al., 2013; Wyss et al., 2013). MPTP: MPTP intoxication (intramuscular low-dose), as previously reported (Borgognon et al., 2017). *Two monkeys in the M1-lesion group were treated with an anti-Nogo-A antibody, as previously reported (Wyss et al., 2013). The PD-like monkeys were all treated with the ANCE cellular therapy, as previously reported (Bloch et al., 2014; Borgognon et al., 2017). **In both PM and M1, the BDA injections covered most of the targeted areas (see Fregosi et al., 2017) and were not preceded by ICMS (intracortical microstimulation) sessions. ***In each monkey, the number of axonal boutons in SC was corrected to take into account the differences in intersections interval (7th row from top), as explained in the “Materials and Methods” section (no corrections for the four monkeys with the injections in PM and five series taken as reference). ****The corrected number of axonal boutons in SC (line above) was finally normalized according to the number of corticospinal BDA labeled axons, as explained in the “Materials and Methods” section. Bold values indicates the most pertinent values.